Further studies are needed to determine whether SIRT1 could be exploited as a target for HBV-related HCC therapy and to assess Nicotinamide possible therapeutic applications in HBV-related HCC treatment. The gene discussed is SIRT1; the disease is hepatocellular carcinoma.